(secondQuint)Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.

5 MG in the Treatment of Prostate Cancer.

 This study is an open-label, multi-center study in which a minimum of 165 patients will receive one (1) of three (3) lots of Oakwood Laboratories' Leuprolide Acetate for Injectable Suspension 22.

5 mg for two cycles.

 A subset of patients (minimum of 12) will be assigned to each lot (A, B or C) and will have additional blood sampling to characterize leuprolide release kinetics for each dose administered.

.

 Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.

5 MG in the Treatment of Prostate Cancer@highlight

The purpose of the study is to demonstrate the safety and efficacy of Leuprolide Acetate for Injectable Suspension 22.

5 mg in reducing serum testosterone to castrate levels in patients with prostate cancer.

